Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Invested Capital (2016 - 2025)

Historic Invested Capital for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to -$29.4 million.

  • Anaptysbio's Invested Capital fell 13486.67% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 13486.67%. This contributed to the annual value of $70.9 million for FY2024, which is 1956.23% down from last year.
  • Latest data reveals that Anaptysbio reported Invested Capital of -$29.4 million as of Q3 2025, which was down 13486.67% from -$44.7 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Invested Capital ranged from a high of $385.7 million in Q2 2021 and a low of -$44.7 million during Q2 2025
  • For the 5-year period, Anaptysbio's Invested Capital averaged around $179.1 million, with its median value being $148.4 million (2023).
  • In the last 5 years, Anaptysbio's Invested Capital surged by 648.59% in 2021 and then plummeted by 55280.9% in 2025.
  • Quarter analysis of 5 years shows Anaptysbio's Invested Capital stood at $356.4 million in 2021, then dropped by 26.46% to $262.1 million in 2022, then plummeted by 66.39% to $88.1 million in 2023, then fell by 19.56% to $70.9 million in 2024, then plummeted by 141.51% to -$29.4 million in 2025.
  • Its last three reported values are -$29.4 million in Q3 2025, -$44.7 million for Q2 2025, and $34.0 million during Q1 2025.